



Fermenta Biotech Limited

CIN: L99999MH1951PLC008485

Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road,
Majiwade, Thane (W) - 400 610, Maharashtra, India.

Tel. : +91-22-6798 0888 Email : info@fermentabiotech.com,

Website. : www.fermentabiotech.com



F.No.:908

August 12, 2025

Corporate Relations
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

Dear Sir,

Sub: Press Release

Ref: Scrip Code 506414

Please find enclosed herewith a 'Press Release' issued by the Company regarding financials of Q1FY26.

Kindly take the above on record.

Thanking you,

Yours faithfully,
For **Fermenta Biotech Limited**

Varadvinayak Khambete
Company Secretary & Head - Legal
Membership No. A33861
Encl: As above

PRESS RELEASE

Fermenta Q1FY26 Consolidated Net Profit INR 21.6 cr against INR 5.9 cr Loss Year Ago

BSE 506414	Bloomberg FERMENTA:IN	Reuters FERM.BO
------------	-----------------------	-----------------

- Q1FY26 Consolidated Revenue INR 145 crore, up 79 % YoY
- Consolidated EBITDA for Q1FY26 INR 37 crore, up 922% YoY

Mumbai, 12 August 2025: Fermenta Biotech Limited, India's leading manufacturer of premium-grade APIs, intermediates, and nutritional premixes for the global markets, today announced its unaudited financial results for the quarter-year ended 30 June 2025 (Q1FY26). Consolidated revenue (other than from real estate) for Q1FY26 was INR 141.5 crore, up 81 % from Q1FY25; EBITDA for Q1FY26 was INR 35.3 crore, up 625% from Q1FY25.

Key financials (consolidated) without real estate segment

	Q1FY26
Revenue	INR 141.5 crore (up 81% YoY, up 6% QoQ)
EBITDA	INR 35.3 crore (up 625% YoY, up 9% QoQ)

Key financials (consolidated) with real estate segment

	Q1FY26
Revenue*	INR 145 crore (up 79 % YoY, up 1 % QoQ)
EBITDA*	INR 37 crore (up 922% YoY, down 9 % QoQ)
Profit after tax**	INR 21.6 crore (vs INR 5.9 crore loss year ago, down 35% QoQ)
EPS after exceptional item**	INR 7.49 (up INR 9.5 YoY, down 37% QoQ)

* Q1FY26 had lower revenue from real estate value unlocking by approx. INR 6 crore over Q4FY25

** Q1FY26 had a **charge** of INR 2.48 crore as against deferred tax **credit** of INR 6.31 crore in Q4FY25

Performance highlights

- Human nutrition volume grew by 83% over Q1FY25 and 8% over Q4FY25.
- Animal nutrition volume grew by 45 % over Q1FY25 and down by 17% over Q4FY25.
- German subsidiary's standalone Q1FY26 revenue was INR 15.7 crore, up 588% from INR 2.3 crore a year ago and 35% over the previous quarter, with EBITDA at INR 5 crore, up 5.9 crore year-on-year and down by 1% quarter-on-quarter.
- Incorporated a wholly owned subsidiary focused on environmental solutions, targeting challenges like waste, water, and air pollution management.
- MoU with NIFTEM-T to establish a Centre of Excellence for Food Fortification, enhancing public nutrition and food security in India.
- Letter of Approval from GAIN, recognizing Fermenta as a global supplier of high-quality premix blends.
- Certificate of Suitability (CEP) from EDQM for VITADEE™ 100 SD premix, opening pathways for European market expansion.

Comment from Prashant Nagre – Managing Director

“Continuing our financial and operational turnaround of FY2024–25, we delivered exceptional performance this quarter with strong YoY growth in revenue and EBITDA, driven by robust volume and price expansion across our human and animal nutrition segments. Fermenta’s strategic initiatives, including partnerships with NIFTEM-T and GAIN, strengthen our market position for sustained future growth.”

Revenue mix (consolidated)

	Q1FY 26 (INR crore)	Q1FY 25 (INR crore)	YoY change (%)	Q4FY25 (INR crore)	QoQ change(%)
Nutrition Business	114.6	62.1	85%	107.7	6%
Vitamin D3 – Human Nutrition	84.7	46.0	84%	75.4	12%
Vitamin D3 – Animal Nutrition	21.4	6.0	256%	23.4	(9)%
Others	8.5	10.0	(15)%	8.9	(4)%
Non-Nutrition Business	18.3	13.9	32%	22.0	(17)%
Other APIs and Intermediates	2.0	3.3	(40)%	1.5	29%
Green Chemistry Solutions / Enzymes	9.8	8.5	15%	11.9	(18)%
Environmental Solutions	6.6	2.1	220%	8.6	(23)%
Others***	10.4	5.0	108%	5.4	92%
Value Unlocking					
Real Estate	1.6	0.0	0%	8.6	(81)%

*** Includes rental income, forex gain, insurance claim received, interest received etc.

Geographical Revenue Mix (consolidated) excluding real estate

	Q1FY26 (%)	Q1FY25 (%)	Change
India	35%	43%	(8)%
Europe	33%	26%	7%
North America	13%	10%	3%
Others	19%	21%	(2)%

About

Fermenta Biotech Limited (www.fermentabiotech.com) delivers best-in-class, science-backed nutritional ingredients across a wide range of market segments, including Pharmaceuticals, Dietary Supplements, Food & Beverages, and Veterinary. State-of-the-art manufacturing facilities located at Kullu (Himachal Pradesh) and Dahej (Gujarat) drive Fermenta’s comprehensive portfolio of premium vitamins, nutritional premixes, and ingredients for Human and Animal Nutrition.

Our products and services cater to the exacting standards of the world’s leading brands for nutritional ingredients that enhance health, support preventive care, and drive life productivity. With decades of expertise at global-scale complex manufacturing, we also provide research-based custom solutions in green chemistry and environmental solutions.